Pull to refresh
Logo
What Changed
Following Why Sign Up
Cue Biopharma's Xolair challenger clears phase 2 in chronic hives

Cue Biopharma's Xolair challenger clears phase 2 in chronic hives

New Capabilities

CUE-221 hit its primary endpoint and showed durable responses; a registration-enabling trial is next

September 21st, 2026: Fierce Biotech reports the phase 2 win

Overview

Updated Oct 6

Cue Biopharma's chronic hives drug CUE-221 hit its primary goal in a 145-patient Phase 2 trial, clearing the way for a registration-enabling study. At the highest dose, 54% of patients had complete resolution of hives at week 12, versus 11% on placebo. On its September 21 investor call, Cue said high-dose patients kept that complete response for 12 weeks after the last dose.

That durability is the pitch against Xolair (omalizumab), the standard add-on therapy, which hit 41% in the same trial. CUE-221 neutralizes free IgE like Xolair, but it also lets IgE bind the CD23 receptor on B cells, cutting off new IgE synthesis. A post hoc analysis at week 28 showed a statistically significant gap over omalizumab, which Cue credits to the second mechanism.

Why it matters

Chronic hives leave millions inadequately controlled on Xolair; CUE-221's dual mechanism aims to offer deeper, longer-lasting relief.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

54%
Complete hive resolution at week 12, 4 mg/kg dose
Versus 11% on placebo (p < 0.005) and 41% on omalizumab in the comparator arm.
41%
Xolair complete resolution in same trial
Omalizumab 300 mg achieved 41% at week 12; not statistically tested against CUE-221.
145
Patients enrolled in the Phase 2 trial
Randomized 2:2:2:1:1 across three CUE-221 doses, placebo, and omalizumab.
$676.5M
Potential milestone payments to Ascendant Health
Cue paid $15 million upfront when it licensed the drug in April 2026, excluding China.
36 pts
Week 28 post hoc gap vs omalizumab
At 4 mg/kg, the difference in complete hive resolution versus omalizumab reached statistical significance 12 weeks after the last dose.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

SP
Shao-Lee Lin, M.D., Ph.D.
President and Chief Executive Officer, Cue Biopharma
Leading CUE-221 toward Phase 2b/3 and food allergy trials after positive Phase 2 results
DP
Dale Umetsu, M.D., Ph.D.
Clinical Professor of Medicine, Stanford University; former Global Lead for XOLAIR development
External supporter of CUE-221's differentiation

Organizations Involved

Cue Biopharma
Cue Biopharma
Clinical-stage biopharmaceutical company
Positive Phase 2 results; planning Phase 2b/3 in CSU and Phase 2 in food allergy

Boston-based biotech developing CUE-221, a dual-mechanism anti-IgE antibody, as a potential challenger to Xolair in allergic diseases.
Genesis Life Sciences / Ascendant Health Limited
Genesis Life Sciences / Ascendant Health Limited
Related biopharmaceutical companies
Ran the Phase 2 trial in China; retains China rights

Conducted the Chinese Phase 2 trial that produced the positive results Cue is now building on.

Timeline

September 2023 September 2026

5 events Latest: September 21st, 2026 · 2 months ago
Tap a bar to jump to that date

  1. Fierce Biotech reports the phase 2 win

    Latest Media

    Coverage frames CUE-221 as a would-be Xolair challenger advancing to a Phase 2b/3 trial.

  2. Investor call details durability data

    Corporate

    Cue told investors high-dose patients kept complete hive resolution for 12 weeks after the last dose, about five half-lives. A week 28 post hoc analysis showed a statistically significant gap over omalizumab, and PK and IgE analyses will come at future medical meetings.

  3. Positive Phase 2 topline results announced

    Clinical

    CUE-221 hit the primary endpoint, with 54% of high-dose patients achieving complete hive resolution at week 12.

  4. Cue licenses Ascendant-221

    Corporate

    Cue Biopharma pays $15 million upfront, up to $676.5 million in milestones, for rights outside China.

  5. Trial registered on China's drug registry

    Regulatory

    The CSU study, protocol UBP-A237-IgE, registered as CTR20233674 targeting 144 patients.

Scenarios

1

CUE-221 confirms efficacy in Phase 2b/3 and files for approval

Possible Resolves by End of 2028

Discussed by: Cue Biopharma management, Fierce Biotech

Cue initiates the registration study, which completes enrollment and meets its primary endpoint against placebo. If the dual mechanism holds at scale, CUE-221 could reach the market as a next-generation anti-IgE with a durability advantage over Xolair. Approval would depend on confirmatory data and safety results with the full 36-week dataset.

2

Phase 2b/3 fails to replicate, echoing ligelizumab's collapse

Possible Resolves by End of 2028

Discussed by: Chaotropy analysis

The Phase 2 enrolled 145 patients, small enough that the gap over omalizumab could shrink or vanish in a larger trial. Novartis's ligelizumab posted strong Phase 2b CSU results that Phase 3 could not confirm, and skeptics note CUE-221's complete-response rates carry wide confidence intervals at this sample size.

3

CUE-221 advances first in food allergy

Likely Resolves by End of 2027

Discussed by: Cue Biopharma strategy, D.G. analyst coverage

Cue has said it plans a Phase 2 study in food allergy, another IgE-driven disease where Xolair is already approved but requires lifelong dosing. A positive result there could give CUE-221 a second indication with a clearer differentiation story than the crowded CSU market.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2017-2023

Ligelizumab's CSU failure (2017-2023)

Novartis's next-generation high-affinity anti-IgE antibody looked like a Xolair killer after a strong Phase 2b in chronic spontaneous urticaria. Phase 3 results then failed to replicate the superiority over omalizumab, and Novartis dropped the CSU program.

Then

Novartis ended the CSU trials and shifted ligelizumab focus to other indications.

Now

The episode became the cautionary tale for any anti-IgE candidate claiming superiority over Xolair based on mid-stage data.

Why this matters now

CUE-221's Phase 2 win mirrors ligelizumab's trajectory, and skeptics point to the small sample size and wide confidence intervals as reason to hold judgment until Phase 2b/3.

March 2014

Xolair's approval for chronic hives (2014)

The U.S. Food and Drug Administration approved omalizumab, sold as Xolair by Roche and Novartis, for chronic spontaneous urticaria in patients who did not respond to antihistamines. It was the first biologic approved for the condition.

Then

Xolair became the standard add-on biologic for CSU, generating billions in annual sales.

Now

It established anti-IgE therapy as the mechanism of choice for the disease and set the efficacy benchmark CUE-221 now compares against.

Why this matters now

CUE-221's trial used Xolair as an active comparator, and its durability advantage at 12 weeks off treatment is aimed at the incumbent's main weakness: patients rebound when dosing stops.

Sources

(7)
+1
Fierce Biotech Cue Biopharma / Globe Newswire Quiver Quantitative Cue Biopharma Chaotropy EarningsCalls.dev Healio